Antibacterial Therapy: Achievements, Problems and Future Perspectives


Book Description

At a symposium in Wuppertal held on 26 September 1995, Dr. Karl-Georg Metzger was honored, on the occasion of his retirement, for his scientific contributions and involvement in antibacterial drug research and develop ment within Bayer AG. In 1963 Dr. Metzger was the first "molecular micro biologist" to join Bayer in the field of antibacterial research. Karl-Georg Metzger studied physics and biology at the University of Mainz from 1950 to 1953 and continued his scientific education, with a grant from the Deutsche Forschungsgemeinschaft, in Frankfurt on Main (1953-1956). From 1956 to 1958, under Professor Kaplan, he worked on his DNA following treatment of PhD, studying on "Energy conduction along bacteria with UV light and X-rays and the formation of mutations". He was awarded his PhD in 1959. From 1958 to 1963 he was research assistant in ra diobiology development at the Institute of Genetics in Cologne. During the following years he became fascinated by the emerging fields of molecular biology and gene technology. He worked together with the molecular gen eticists W. Harms and M. Delbriick, who built up one of the most renowned institutes in the world, in Cologne. ''An incredibly interesting time:' Dr. Metzger remembers, in which he got to know a whole series of Nobel prize winners from Niels Bohr to Watson and Crick and Joshua Lederberg, the first to recombine genotypes of bacteria.




Antibiotic Development and Resistance


Book Description

The increasing resistance of bacteria towards all current classes of antibiotics is now a serious health problem in both developed and developing countries. Antibiotic Development and Resistance presents 15 chapters that explore the medical issues raised by this development and review the relevant literature. The book begins by reviewing the global







Advances in Phage Therapy: Present Challenges and Future Perspectives


Book Description

This Research Topic is dedicated to Prof. Elisabeth Kutter on the occasion of her 80th birthday. Dr. Kutter’s career as a phage scientist has extended nearly 60 years. She has been a pioneer as a woman in science. She started to work with phage at the University of Rochester, New York working with Dr. Wiberg on radioisotopes making excellent progress in the field – progress which was even cited in Luria’s 1969 Nobel Prize talk. Betty first encountered phage therapy during a visit to Georgia in 1990 which was part of a longer stay in the former Soviet Union under a US-USSR research exchange program. Dr. Kutter was one of the first Americans to advocate for phage therapy in the post antibiotic era. Betty started hosting the Evergreen International Phage meetings in Olympia, Washington, from 1975 onward, which helped to develop a strong phage community with participation increasing over the years to 350 at the 23 rd biannual last year. Betty continues to be an active member in the phage community, sharing her experience and working with all of us toward her ultimate goal of making phage therapy available worldwide thus reducing the burden caused by antibiotic resistant bacterial infections.




Nanostructures for Antimicrobial Therapy


Book Description

Nanostructures for Antimicrobial Therapy discusses the pros and cons of the use of nanostructured materials in the prevention and eradication of infections, highlighting the efficient microbicidal effect of nanoparticles against antibiotic-resistant pathogens and biofilms. Conventional antibiotics are becoming ineffective towards microorganisms due to their widespread and often inappropriate use. As a result, the development of antibiotic resistance in microorganisms is increasingly being reported. New approaches are needed to confront the rising issues related to infectious diseases. The merging of biomaterials, such as chitosan, carrageenan, gelatin, poly (lactic-co-glycolic acid) with nanotechnology provides a promising platform for antimicrobial therapy as it provides a controlled way to target cells and induce the desired response without the adverse effects common to many traditional treatments. Nanoparticles represent one of the most promising therapeutic treatments to the problem caused by infectious micro-organisms resistant to traditional therapies. This volume discusses this promise in detail, and also discusses what challenges the greater use of nanoparticles might pose to medical professionals. The unique physiochemical properties of nanoparticles, combined with their growth inhibitory capacity against microbes has led to the upsurge in the research on nanoparticles as antimicrobials. The importance of bactericidal nanobiomaterials study will likely increase as development of resistant strains of bacteria against most potent antibiotics continues. - Shows how nanoantibiotics can be used to more effectively treat disease - Discusses the advantages and issues of a variety of different nanoantibiotics, enabling medics to select which best meets their needs - Provides a cogent summary of recent developments in this field, allowing readers to quickly familiarize themselves with this topic area










Issues in Antibiotics, Antiinfectives, Antimicrobials, and Antivirals: 2011 Edition


Book Description

Issues in Antibiotics, Antiinfectives, Antimicrobials, and Antivirals: 2011 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Antibiotics, Antiinfectives, Antimicrobials, and Antivirals. The editors have built Issues in Antibiotics, Antiinfectives, Antimicrobials, and Antivirals: 2011 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Antibiotics, Antiinfectives, Antimicrobials, and Antivirals in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Issues in Antibiotics, Antiinfectives, Antimicrobials, and Antivirals: 2011 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.







How to Overcome the Antibiotic Crisis


Book Description

This volume focuses on antibiotics research, a field of topical significance for human health due to the worrying increase of nosocomial infections caused by multi-resistant bacteria. It covers several basic aspects, such as the evolution of antibiotic resistance and the influence of antibiotics on the gut microbiota, and addresses the search for novel pathogenicity blockers as well as historical aspects of antibiotics. Further topics include applied aspects, such as drug discovery based on biodiversity and genome mining, optimization of lead structures by medicinal chemistry, total synthesis and drug delivery technologies. Moreover, the development of vaccines as a valid alternative therapeutic approach is outlined, while the importance of epidemiological studies on important bacterial pathogens, the problems arising from the excessive use of antibiotics in animal breeding, and the development of innovative technologies for diagnosing the “bad bugs” are discussed in detail. Accordingly, the book will appeal to researchers and clinicians alike.